NIH awards $12.2M for Biomedical R&D to Emergent Product Development, a definitive contract
Contract Overview
Contract Amount: $12,196,302 ($12.2M)
Contractor: Emergent Product Development Gaithersburg Inc.
Awarding Agency: Department of Health and Human Services
Start Date: 2007-09-21
End Date: 2011-12-31
Contract Duration: 1,562 days
Daily Burn Rate: $7.8K/day
Competition Type: FULL AND OPEN COMPETITION
Number of Offers Received: 4
Pricing Type: COST PLUS FIXED FEE
Sector: R&D
Official Description: BIOMEDICAL (BASIC)
Place of Performance
Location: GAITHERSBURG, MONTGOMERY County, MARYLAND, 20879
State: Maryland Government Spending
Plain-Language Summary
Department of Health and Human Services obligated $12.2 million to EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. for work described as: BIOMEDICAL (BASIC) Key points: 1. Spending focuses on Research and Development in Physical, Engineering, and Life Sciences. 2. The contract was awarded under full and open competition. 3. The primary contractor is Emergent Product Development. 4. This award represents a small portion of the overall NIH budget for R&D.
Value Assessment
Rating: fair
The contract type is Cost Plus Fixed Fee, which can lead to cost overruns if not managed carefully. The award amount of $12.2M for a 4-year period suggests a moderate investment in R&D.
Cost Per Unit: N/A
Competition Analysis
Competition Level: full-and-open
The contract was awarded through full and open competition, indicating a robust price discovery process. This method generally ensures competitive pricing by allowing all eligible vendors to bid.
Taxpayer Impact: Taxpayer funds are being used for critical biomedical research, with the potential for significant public health benefits. The competitive award process aims to ensure efficient use of these funds.
Public Impact
Supports advancements in biomedical research, potentially leading to new treatments or technologies. Funding directed towards a specific company, Emergent Product Development, for specialized R&D. The contract duration of over 4 years indicates a long-term research objective.
Waste & Efficiency Indicators
Waste Risk Score: 78 / 10
Warning Flags
- Cost Plus Fixed Fee contract type can incentivize higher costs.
- Long contract duration may present risks if project scope changes.
Positive Signals
- Awarded under full and open competition.
- Supports critical R&D in the life sciences sector.
Sector Analysis
This spending falls within the Research and Development sector, specifically focusing on physical, engineering, and life sciences. Benchmarks for R&D contracts vary widely based on scope and duration, but $12.2M over four years is a substantial investment for a single project.
Small Business Impact
The data does not indicate if small businesses were involved as subcontractors or partners in this contract. The primary awardee is Emergent Product Development, whose size relative to small business status is not specified.
Oversight & Accountability
The contract was awarded by the National Institutes of Health (NIH), a major agency within HHS, suggesting established oversight mechanisms. However, the specific oversight details for this definitive contract are not provided.
Related Government Programs
- Research and Development in the Physical, Engineering, and Life Sciences
- Department of Health and Human Services Contracting
- National Institutes of Health Programs
Risk Flags
- Cost Plus Fixed Fee contract type.
- Long contract duration (over 4 years).
- Lack of specific detail on expected outcomes.
- No information on small business participation.
Tags
research-and-development-in-the-physical, department-of-health-and-human-services, md, definitive-contract, 10m-plus
Frequently Asked Questions
What is this federal contract paying for?
Department of Health and Human Services awarded $12.2 million to EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.. BIOMEDICAL (BASIC)
Who is the contractor on this award?
The obligated recipient is EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC..
Which agency awarded this contract?
Awarding agency: Department of Health and Human Services (National Institutes of Health).
What is the total obligated amount?
The obligated amount is $12.2 million.
What is the period of performance?
Start: 2007-09-21. End: 2011-12-31.
What specific biomedical advancements are expected from this $12.2M investment, and how will their success be measured?
The specific advancements are not detailed in the provided data. Success measurement would typically involve milestones outlined in the Cost Plus Fixed Fee contract, focusing on research progress, data generation, and potential for future development. NIH program officers would monitor adherence to research protocols and achievement of defined objectives.
What are the potential risks associated with a Cost Plus Fixed Fee contract for long-term R&D, and how are they mitigated?
Risks include potential cost overruns if the contractor's actual costs exceed projections, as the government pays the fixed fee plus actual costs. Mitigation involves rigorous monitoring of expenditures, clear definition of contract scope, and performance metrics to ensure the contractor remains efficient and focused on achieving research goals within budget constraints.
How does this contract contribute to the overall strategic goals of the National Institutes of Health in biomedical research?
This contract likely supports NIH's mission to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and prevent illness. The specific R&D focus aligns with NIH's strategic priorities in areas like disease prevention, treatment development, or basic biological understanding.
Industry Classification
NAICS: Professional, Scientific, and Technical Services › Scientific Research and Development Services › Research and Development in the Physical, Engineering, and Life Sciences
Product/Service Code: RESEARCH AND DEVELOPMENT › N – Health R&D Services
Competition & Pricing
Extent Competed: FULL AND OPEN COMPETITION
Solicitation Procedures: BASIC RESEARCH
Offers Received: 4
Pricing Type: COST PLUS FIXED FEE (U)
Evaluated Preference: NONE
Contractor Details
Parent Company: Emergent Biosolutions Inc. (UEI: 173570271)
Address: 300 PROFESSIONAL DR # 100, GAITHERSBURG, MD, 20879
Business Categories: Category Business, Small Business
Financial Breakdown
Contract Ceiling: $12,196,302
Exercised Options: $12,196,302
Current Obligation: $12,196,302
Contract Characteristics
Multi-Year Contract: Yes
Commercial Item: COMMERCIAL ITEM PROCEDURES NOT USED
Cost or Pricing Data: NO
Timeline
Start Date: 2007-09-21
Current End Date: 2011-12-31
Potential End Date: 2011-12-31 00:00:00
Last Modified: 2021-09-01
More Contracts from Emergent Product Development Gaithersburg Inc.
- Federal Contract — $1.4B (Department of Health and Human Services)
- Acam2000, Smallpox (vaccinia) Vaccine, Live (acam) — $804.9M (Department of Health and Human Services)
- Medical Countermeasures (MCM) That CAN BE Deployed in the Event of a Filovirus Outbreak ARE a Crucial Component to the United States Government?s (usg?s) Outbreak Response Plan. Biomedical Advanced Research and Development Authority (barda) IS Seekin — $118.6M (Department of Health and Human Services)
- TAS::75 0140::TAS Advanced Development of Recombinant Protective Antigent (RPA) Anthrax Vaccine CAN 1990087 — $93.0M (Department of Health and Human Services)
- FOR Other Functionsthis Contract IS for the Advanced Development of Nuthrax (anthrax Vaccine Absorbed With CPG 7909) or AV7909 — $43.8M (Department of Health and Human Services)
View all Emergent Product Development Gaithersburg Inc. federal contracts →
Other Department of Health and Human Services Contracts
- Contact Center Operations (CCO) — $5.5B (Maximus Federal Services, Inc.)
- TAS::75 0849::TAS Oper of Govt R&D Goco Facilities — $4.8B (Leidos Biomedical Research Inc)
- THE Purpose of This Contract IS to Provide the Full Complement of Services Necessary to Care for UC in ORR Custody Including Facilities Set-Up, Maintenance, and Support Internal and Perimeter (IF Applicable) Security, Direct Care and Supervision Inc — $3.5B (Rapid Deployment Inc)
- Contact Center Operations — $2.6B (Maximus Federal Services, Inc.)
- Federal Contract — $2.4B (Leidos Biomedical Research Inc)
View all Department of Health and Human Services contracts →